U.S. Auto Stock News

Amphastar Pharmaceuticals (AMPH) has drawn fresh attention after signing an exclusive license agreement with Nanjing Hanxin Pharmaceutical for AMP-110, a synthetic hormone analog for inflammatory and autoimmune diseases in the U.S. and Canada. See our latest analysis for Amphastar Pharmaceuticals. The AMP-110 announcement came after a 19.6% 90 day share price return and a recent 5.8% intraday move on the news. The 1 year total shareholder return of a 23.4% decline shows longer term holders...

Genuine Parts (GPC) has scheduled a future leadership change, with Non Executive Chairman Paul D. Donahue set to retire in 2026 and current CEO Will Stengel slated to assume the combined Chairman and CEO role. See our latest analysis for Genuine Parts. The leadership timeline sits against a share price of $133.8, with a 7.90% year to date share price return and a 17.66% one year total shareholder return. This suggests momentum has been building recently, despite a weaker three year total...

Recent attention on Targa Resources (TRGP) was sparked by Oakmark Select Fund’s latest investor letter and a consensus “Outperform” view from multiple brokerages, which together helped refocus the market on this midstream operator. See our latest analysis for Targa Resources. The recent 3.62% one day share price move and consensus “Outperform” calls sit against a mixed picture, with a 24.94% 90 day share price return but a 1 year total shareholder return of 9.09% decline, so momentum looks...

In its third quarter of fiscal 2026, reported in the past, Rubrik delivered a beat-and-raise performance, shifting from a non-GAAP net loss to non-GAAP net income on the back of demand for its cybersecurity and AI offerings, and lifted its full-year revenue outlook while narrowing its expected adjusted net loss. What stands out is that Rubrik’s progress reflects not just higher customer interest in data security, but also operational improvements strong enough to prompt management to tighten...

Compass Therapeutics has appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer, with both roles effective January 1, 2026, adding experienced oncology leadership across commercial and clinical development functions. These hires bring deep experience in successful oncology drug launches and advancing immuno-oncology programs through pivotal trials and regulatory approvals, potentially strengthening Compass Therapeutics’ execution capabilities. Next,...

The US Defense Department's US$400 million equity investment in MP Materials (MP), together with proposed government stockpiles of critical minerals, has pushed the rare earth producer back into the spotlight for many investors. See our latest analysis for MP Materials. Those policy moves have coincided with a sharp swing in sentiment toward MP Materials, with a 1 month share price return of 30.12% and a year to date share price return of 26.07%, even though the 3 month share price return...

On January 6, 2026, CF Industries Holdings announced that executive vice president and chief financial officer Gregory D. Cameron would depart the company on February 15, 2026, with long-time vice president, corporate controller and chief accounting officer Richard A. Hoker stepping in as interim CFO. This leadership transition comes as CF Industries pursues low-carbon ammonia initiatives and responds to shifting fertilizer market conditions and analyst reassessments. Next, we’ll examine how...

Share repurchases and capital management signal KE Holdings (BEKE) recently confirmed its Class A share count at about 3.37 billion as of January 2, 2026, while detailing substantial on-market repurchases between November and early January that highlight active capital management. See our latest analysis for KE Holdings. KE Holdings shares currently trade at $17.32, with a 7.85% year to date share price return and a 5.77% total shareholder return over the past year, but a 75.02% total...

Alphabet (NasdaqGS:GOOGL) just signed a multi-year deal that puts its Gemini AI models and cloud infrastructure at the core of Apple’s upcoming Apple Intelligence features, including a major Siri overhaul. See our latest analysis for Alphabet. Alphabet’s recent Apple deal comes on top of a strong run, with the share price at $335.84 and a 90 day share price return of 32.59%, while the 1 year total shareholder return of 74.77% points to momentum that has been building rather than fading. If...

Power Integrations (POWI) has appointed Chris Jacobs as Senior Vice President for Marketing and Product Strategy, bringing experience from Micron Technology and more than 25 years at Analog Devices into the company’s leadership team. See our latest analysis for Power Integrations. The executive appointment comes as the share price trades at US$42.10, with a 1 month share price return of 15.85% and a year to date share price return of 12.87%. This is set against a 1 year total shareholder...

GlobalFoundries (GFS) has drawn fresh investor attention after appointing veteran semiconductor executive Ganesh Moorthy to its board, an event that puts boardroom experience and long term execution firmly in focus. See our latest analysis for GlobalFoundries. The appointment of Moorthy comes as GlobalFoundries’ share price trades at US$41.35, with a 30 day share price return of 11.04% and a 90 day share price return of 19.60%, suggesting building momentum despite a 1 year total shareholder...

EPR Properties’ Board of Trustees has declared a past monthly cash dividend of US$0.295 per common share, payable on February 17, 2026 to shareholders of record as of January 30, 2026, equivalent to an annualized US$3.54 per share. This reaffirmed payout, alongside recent balance sheet moves and operational updates, underlines the REIT’s continued emphasis on consistent income for shareholders. We’ll now examine how the reaffirmed monthly dividend interacts with EPR’s experiential-focused...

Why Houlihan Lokey (HLI) is on investors’ radar today Houlihan Lokey (HLI) has been drawing attention after a mixed pattern in recent returns, with a small 1 day gain, softer performance over the past week, and modest moves over the past month and past 3 months. See our latest analysis for Houlihan Lokey. At a share price of $182.60, Houlihan Lokey’s recent 1 month and year to date share price returns in the low single digits sit against a 1 year total shareholder return of 5.54% and a very...

In early January 2026, Burford Capital Limited completed the private pricing of US$500 million of senior unsecured notes due 2034, guaranteed by the parent, with proceeds earmarked primarily to redeem its existing 5.000% bonds maturing in 2026 and to repay other debt or fund general corporate purposes. This refinancing meaningfully reshapes Burford’s debt profile by extending maturities and potentially enhancing financial flexibility as it continues to fund large, complex legal-finance...

Why Associated Banc-Corp is on investors’ radar today Associated Banc-Corp (ASB) has drawn fresh attention after recent share price moves, with the stock last closing at $26.30. This has prompted investors to reassess how its current valuation lines up with recent returns. See our latest analysis for Associated Banc-Corp. While the latest move to $26.30 comes with a 1-day share price return of 1.11%, the 30-day share price return of a 2.38% decline contrasts with a 90-day gain of 9.08%. The...

ON Semiconductor (ON) is in the spotlight as it pivots from lower margin commodity chips toward higher value power and sensing products for electric vehicles, AI data centers, and industrial automation. See our latest analysis for ON Semiconductor. The recent 1 day share price return of 1.97% to US$60.58 follows a 30 day share price return of 9.97% and a 90 day gain of 14.37%, while the 1 year total shareholder return of 9.69% contrasts with a weaker 3 year total shareholder return of an...

Event context and recent share performance Pharvaris (PHVS) has been drawing attention after recent share price moves, with the stock closing at US$25.63 and showing mixed short term returns, including a 1 day decline and gains over the past week. See our latest analysis for Pharvaris. Those short term moves sit against a mixed backdrop, with a 30 day share price return of 7.24% and a year to date share price return of a 3.21% decline. At the same time, the 1 year total shareholder return of...

Why Builders FirstSource Is On Investors’ Radar Today Builders FirstSource (BLDR) is drawing fresh attention after recent trading, with the share price at $126.38 and returns over the past month, past 3 months, and year giving investors new performance context. See our latest analysis for Builders FirstSource. For context, Builders FirstSource has seen strong near term momentum, with a 7 day share price return of 20.30% and a 30 day share price return of 20.75%. The 1 year total shareholder...

CareDx (CDNA) has attracted fresh attention after issuing preliminary fourth quarter and full year 2025 guidance, flagging roughly $108 million in quarterly revenue and about $380 million for the year, with double digit year-over-year growth. See our latest analysis for CareDx. The guidance and recent ImmuneScape collaboration with 10x Genomics come after a strong 90 day share price return of 35.56%, although the 1 year total shareholder return sits at a 10.48% decline and the 3 year total...

What Cushman & Wakefield’s Recent Performance Tells Investors Cushman & Wakefield (CWK) has been drawing attention after a mixed short term share performance, with a 1 day decline and 7 day pullback, alongside gains over the past month and past 3 months. See our latest analysis for Cushman & Wakefield. At a share price of $16.36, Cushman & Wakefield shows a short term loss of momentum. The recent pullback contrasts with a positive year to date share price return and a much stronger 1 year...

Palladyne AI recently raised its full-year 2026 revenue guidance to US$24.0 million–US$27.0 million and announced the commercial launch of its next-generation industrial autonomy platform, Palladyne IQ 2.0, following late-2025 acquisitions of GuideTech, Warnke Precision Machining, and MKR Fabricators. Together, the higher guidance and IQ 2.0 rollout highlight a rapid shift in Palladyne AI’s business mix toward scalable, embodied AI solutions across defense and industrial markets. We’ll now...

Cimpress plc recently announced that it will release its Q2 FY2026 results and has already held a public Q&A call on January 29, 2026, while also revealing that National Pen and BuildASign will combine capabilities to enhance VistaPrint’s higher-value product offerings. By uniting these subsidiaries under shared leadership and capabilities, Cimpress is aiming to extract deeper synergies in areas like promotional products, logo apparel, merch, signage, and packaging. We’ll now examine how...

NovoCure (NVCR) has drawn fresh attention after reporting record 2025 revenues of $655 million, appointing Frank Leonard as CEO, and advancing FDA submissions for its tumor treating fields therapies. See our latest analysis for NovoCure. Those record 2025 revenues and the new CEO appointment come after a mixed year in the market, with a 30 day share price return of 6.17% and a 1 year total shareholder return decline of 47.74%. This suggests long term investors are still reassessing risk even...

AAR Corp. recently reported second-quarter fiscal 2026 results showing higher sales of US$795.3 million and a return to profitability, while reaffirming its focus on funding organic growth across parts distribution, maintenance and repair, and software offerings. Management also emphasized that mergers and acquisitions remain central to AAR’s growth plans, highlighting self-sourced deals, clear acquisition criteria, and confidence in the company’s ability to integrate new businesses...